Last reviewed 2026-04-20 · How we verify

Nebulicina (FENOXAZOLINE)

Phase 2 active Small molecule

Nebulicina (generic name: FENOXAZOLINE) is a fenoxazoline drug. It is currently in Phase 2 development.

Nebulicina works by binding to the Nischarin protein, disrupting its function.

Nebulicina, also known as Fenoxazoline, is a small molecule drug that targets Nischarin. It belongs to the fenoxazoline class and its mechanism of action is not well-documented. As it is not FDA-approved, there is limited information available on its commercial status, approved indications, half-life, bioavailability, and generic manufacturers. Further research is needed to understand its potential therapeutic applications and safety profile. The current owner of Nebulicina is not specified.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	FENOXAZOLINE
Drug class	fenoxazoline
Target	Nischarin
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Think of Nischarin like a key that unlocks a door. Nebulicina is like a lock that blocks the key from working, preventing the door from opening. This can help stop a process that's causing a disease.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Nebulicina CI brief — competitive landscape report
Nebulicina updates RSS · CI watch RSS

Frequently asked questions about Nebulicina

What is Nebulicina?

Nebulicina (FENOXAZOLINE) is a fenoxazoline drug.

How does Nebulicina work?

Nebulicina works by binding to the Nischarin protein, disrupting its function.

What is the generic name of Nebulicina?

FENOXAZOLINE is the generic (nonproprietary) name of Nebulicina.

What drug class is Nebulicina in?

Nebulicina belongs to the fenoxazoline class. See all fenoxazoline drugs at /class/fenoxazoline.

What development phase is Nebulicina in?

Nebulicina is in Phase 2.

What does Nebulicina target?

Nebulicina targets Nischarin and is a fenoxazoline.

Drug class: All fenoxazoline drugs
Target: All drugs targeting Nischarin
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing